Cevimeline


CAS No. : 107233-08-9

Cevimeline,107233-08-9
Product Details
For research use only. Not Intended for Therapeutic Use!
Cat No:I000333
Synonyms:SNI-2011; SNI 2011; (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3/'-quinuclidine]
Molecular Formula:C10H17NOS
Molecular Weight:199.32
Target:Muscarinic Receptor
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Purity: >98%
Cat No:I000333
Cas No:107233-08-9
Product-Name:Cevimeline
InChI:1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3/t8-,10-/m0/s1
InChIKey:WUTYZMFRCNBCHQ-WPRPVWTQSA-N
SMILES:CC1OC2(CN3CCC2CC3)CS1
Cevimeline (cas 107233-08-9), also known as SNI-2011, is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. Cevimeline stimulates the peripheral muscarinic acetylcholine receptors of salivary glands and increases the concentration of Ca+2 in parotic acini and duct cells of rats.  It is used in the treatment of dry mouth associated with sjogren/'s syndrome. 
1. Nihon Yakurigaku Zasshi. 2002 Oct;120(4):253-8.
[Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
Shiozawa A(1).
Author information:
(1)Scientific Affairs Department Pharmaceuticals Group, Nippon Kayaku Co. Ltd., Tokyo Fujimi Bldg., 11-2, Fujimi 1-Chome, Chiyoda-ku, Tokyo 102-8172, Japan. akira.shiozawa@nipponkayaku.co.jp
Cevimeline hydrochloride hydrate is a muscarinic receptor agonist with a chemical structure of a quinuclidine. Intraduodenal administration of cevimeline hydrochloride hydrate dose-dependently increased salivary secretion in normal mice and rats, two strains of autoimmune disease mice, and X-irradiated rats. The clinical efficacy of the cevimeline hydrochlide hydrate at 30 mg t.i.d. during 4 weeks has been demonstrated in double blind comparative study with placebo. In addition, its treatments in 52 weeks have increased salivary flow and improved subjective and objective symptoms of patients with xerostomia in Sjögren/'s syndrome.
2. Adv Exp Med Biol. 2002;506(Pt B):1107-16.
Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren/'s syndrome.
Fox RI(1).
Author information:
(1)Allergy and Rheumatology Clinic, Scripps Memorial Hospital and Research Foundation, La Jolla, California, USA.
Related Products
  • CAS No. :338747-41-4
    Product Name:

    BQCA

    Cat No: R061590 View details
  • CAS No. :1135242-13-5
    Product Name:

    VU0357017 hydrochloride

    Cat No: I000509 View details
  • CAS No. :633283-39-3
    Product Name:

    3-Amino-N-[(4-chlorophenyl)methyl]-4,6-dimethylthieno[2,3-b]pyridine-2-carboxamide

    Cat No: R041504 View details
  • CAS No. :242478-38-2
    Product Name:

    Solifenacin succinate

    Cat No: A000379 View details